AUS
NZ
UK
CA
USA
IND
Highlights
- Breakthrough results from Phase 1b trial of azer-cel
- Durable cancer remission observed in multiple patients
- Next step: pivotal registration study discussions with FDA
Imugene (ASX:IMU) has shared encouraging updates from its Phase 1b clinical trial of azer-cel, aimed at treating relapsed diffuse large B-cell lymphoma (DLBCL). This form of blood cancer is particularly aggressive, often returning after multiple lines of therapy. The latest trial results have drawn significant attention from the medical and investment community, with some considering the company’s work as an important development in the healthcare sector.
Within the study, all newly evaluated patients demonstrated either complete or partial responses to the treatment. This reinforces earlier findings and highlights the potential for long-term remission in cases where other therapies have failed. Notably, one patient — the first ever to receive azer-cel — has remained cancer-free for over a year after the initial dose.
Long-Term Remission and Next Steps
Sustained Response in Challenging Cases
The durability of the treatment’s effect is a standout feature in this trial update. Several patients have maintained remission beyond the one-year mark, and others are approaching similar milestones. Even partial responses, which reflect significant reduction of disease, offer renewed hope for improved quality of life and potential for further recovery.
Regulatory Pathway and Broader Use Exploration
Imugene is now preparing for a pivotal stage in its development roadmap — an end-of-year meeting with the US Food and Drug Administration (FDA) to discuss pivotal registration studies. These discussions will be crucial in defining the treatment’s regulatory pathway.
The company also intends to explore the use of azer-cel earlier in treatment cycles, including in patients who have not undergone autologous CAR-T therapy. This could broaden the reach of the therapy and provide more options for individuals facing difficult cancer diagnoses. For those tracking developments in the top ASX100 landscape, such medical breakthroughs often serve as key points of interest in evaluating healthcare sector advancements.
Frequently Asked Questions
- What type of cancer is azer-cel being tested for?
Azer-cel is being studied for the treatment of relapsed diffuse large B-cell lymphoma (DLBCL), a form of aggressive blood cancer. - How does azer-cel work in patients who have failed other therapies?
It is designed to trigger the immune system to target and eliminate cancer cells, showing results even in patients who have not responded to multiple previous treatments. - What are the next steps for azer-cel’s development?
The company plans to meet with the FDA to discuss pivotal registration studies and explore its use earlier in the treatment process.
